Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.
European urology focus. 2024 Aug 17 [Epub ahead of print]
Fred Saad
Department of Surgery, University of Montreal Hospital Center, Montreal, Canada. Electronic address: .